|1.||Humphreys, Robin: 9 articles (01/2013 - 08/2005)|
|2.||Kakehi, Yoshiyuki: 4 articles (04/2012 - 02/2007)|
|3.||Engesæter, Birgit: 3 articles (02/2013 - 01/2012)|
|4.||Flørenes, Vivi Ann: 3 articles (02/2013 - 01/2012)|
|5.||Wu, Xiu-Xian: 3 articles (04/2012 - 12/2007)|
|6.||Zhao, Xiangxuan: 2 articles (01/2015 - 01/2011)|
|7.||Liu, Chen: 2 articles (01/2015 - 01/2011)|
|8.||Humphreys, R: 2 articles (07/2013 - 02/2006)|
|9.||Emilsen, Elisabeth: 2 articles (02/2013 - 04/2012)|
|10.||Dicker, David T: 2 articles (01/2013 - 08/2011)|
11/20/2012 - "This phase I dose-escalation study examined the safety, tolerability, pharmacokinetics, and immunogenicity of lexatumumab at doses up to, but not exceeding, the adult maximum-tolerated dose (3, 5, 8, and 10 mg/kg), administered once every 2 weeks to patients age≤21 years with recurrent or progressive solid tumors. "
11/20/2012 - "Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors."
02/01/2010 - "This phase 1, dose escalation study assessed the safety, tolerability, pharmacokinetics (PKs) and immunogenicity of lexatumumab administered i.v. every 14 days in patients with advanced solid tumors. "
02/01/2010 - "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors."
10/15/2007 - "Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers."
|2.||Kidney Neoplasms (Kidney Cancer)
|3.||Melanoma (Melanoma, Malignant)
02/01/2013 - "In summary our results suggest that combinational treatment with anicomycin and lexatumumab represents a novel therapeutic strategy in the treatment of melanoma."
04/13/2012 - "These results indicate that CD437 has a strong anti-neoplastic effect alone and in combination with lexatumumab in melanoma cell lines."
02/01/2013 - "In the present study, metastatic melanoma cell lines were treated with lexatumumab (Human Genome Sciences, Inc.) a high-affinity monoclonal antibody agonistic to TRAIL receptor 2 (DR5). "
01/01/2012 - "Combining DTIC and lexatumumab induced an additive or synergistic effect on cell death in the various melanoma cell lines. "
01/01/2012 - "Our data indicated that melanoma cell lines tend to be resistant to mapatumumab, most likely due to low expression of DR4, while a dose dependent response to lexatumumab was observed. "
|4.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/2012 - "Our past study indicated that low concentrations of doxorubicin sensitized renal cell carcinoma (RCC) cells to lexatumumab-mediated apoptosis. "
04/01/2012 - "Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array."
06/18/2007 - "Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model."
02/01/2006 - "We investigate the susceptibility of human renal cell carcinoma (RCC) cells to TRM-1 and HGS-ETR2, 2 human monoclonal agonistic antibodies specific for TRAIL-R1 and TRAIL-R2, respectively. "
12/01/2007 - "Treatment of the ACHN human renal cell carcinoma (RCC) cell line with agonistic TRAIL-R2 antibody (lexatumumab) in combination with 5-fluorouracil, vinblastine, paclitaxel, or docetaxel did not overcome resistance to these agents. "
|5.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2007 - "This compound added alone elicited only a weak proapoptotic effect; however, it strongly synergizes with tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or agonistic TRAILR2 antibody (Lexatumumab) in inducing apoptosis of ovarian cancer cells. "
03/01/2010 - "The results of our study showed that the large majority of primary ovarian cancers are clearly sensitive to the pro-apoptotic action of bortezomib, whose effects are potentiated by the concomitant addition of TRAIL or mapatumumab or lexatumumab. "
03/01/2010 - "We explored the sensitivity of primary ovarian cancer cells to a combination of bortezomib (also known as PS-341), a proteasome inhibitor and TRAIL, a death ligand, or mapatumumab or lexatumumab, TRAIL-R1 or TRAIL-R2 targeting agonist monoclonal antibodies, respectively. "
|1.||TNF-Related Apoptosis-Inducing Ligand Receptors
|5.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||sorafenib (BAY 43-9006)
|1.||Heterologous Transplantation (Xenotransplantation)